Study points to DNA test for myelodysplasia blood disorder:
This article was originally published in Clinica
Executive Summary
A US team is working on a promising DNA test for the early diagnosis of a serious blood disorder that can lead to bone marrow failure and acute myelogenous leukemia. Myelodysplastic syndrome, diagnosed in about 15,000 to 20,000 people a year, is often difficult to distinguish from readily treatable, nonmalignant forms of bone marrow disease. Therapeutic options for the condition are expected to be improved with early diagnosis. The new test, described in the Proceedings of the National Academy of Sciences (April 6), is being developed by researchers from the Pacific Northwest Research Institute in Seattle. It is performed on white cells extracted from a small volume of the patient's blood. The DNA is analysed by a technique called Fourier transform-infrared (FT-IR) spectroscopy in conjunction with statistical models.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.